Mankind Pharma plans billion-dollar acquisition of Bharat Serums & Vaccines

The Indian company Mankind Pharma has selected Barclays and Deutsche Bank as partners for the financing of its planned acquisition of Bharat Serums & Vaccines. According to confidential information, the transaction is valued at approximately 138 billion rupees, equivalent to around 1.6 billion US dollars. These financial institutions will not only provide loans for the acquisition but also organize the sale of rupee-denominated bonds. Additionally, Mankind Pharma is considering the potential sale of shares and the use of its own funds to finance the deal. Negotiations are still ongoing, and no final decisions have been made yet, emphasized an unnamed source.